Fosamax Osteonecrosis of the Jaw Settlement Criteria Explained

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Historical Context and Legacy of Health Information

The Immunodeficiency Foundation has long served as a trusted repository for general health and science information, curating a broad archive that spans foundational immunology, public health milestones, and evolving therapeutic landscapes. Its editorial mission has consistently emphasized the importance of understanding how biological systems interact with environmental and pharmaceutical factors over time. Within this legacy, the Foundation’s archival materials have documented the gradual shift from population-level health guidance toward more individualized risk assessments, particularly as medical interventions became more targeted and their long-term consequences more apparent. This historical perspective provides a critical backdrop for examining specific exposure scenarios that emerge from routine clinical practice.

Bridging to Fosamax and Osteonecrosis of the Jaw

One such scenario involves the prolonged use of bisphosphonate therapies, originally developed to manage bone density disorders, which later became associated with unexpected adverse outcomes in certain patient populations. As the archive’s scope expanded to include pharmacovigilance data, it became evident that therapeutic exposures—such as those encountered by patients receiving high-dose or long-term bisphosphonate regimens—warranted closer scrutiny. The transition from general health education to focused exposure analysis is therefore a natural extension of the Foundation’s commitment to documenting the full spectrum of health determinants, including those arising from medical treatments themselves. Fosamax (alendronate) is a bisphosphonate medication prescribed to treat osteoporosis. A known adverse effect associated with its use is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw.

Clinical Presentation and Diagnosis of Osteonecrosis of the Jaw

Osteonecrosis of the jaw presents as exposed bone in the oral cavity that fails to heal within eight weeks after identification by a healthcare provider. The condition can occur spontaneously but is generally associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is primarily clinical, based on visual examination of the oral cavity and patient history. Imaging studies, such as panoramic radiographs or CT scans, may be used to assess the extent of bone involvement. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, though a subset may have recurrence of symptoms if rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Fosamax Pharmacology and Reported Adverse Effects

Fosamax (alendronate) works by inhibiting osteoclast-mediated bone resorption, which reduces bone turnover. This mechanism is beneficial for treating osteoporosis but can also impair the normal remodeling of jawbone. Multiscale characterization of jawbone in animal models has shown that bisphosphonate treatment does not substantially change jawbone characteristics compared to untreated controls, though it may affect tissue mineral density distribution near the periodontal ligament (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings suggest that the jawbone's response to bisphosphonates differs from that of other skeletal sites, such as the lumbar vertebrae (https://pubmed.ncbi.nlm.nih.gov/40345077/). The reported adverse effect of ONJ has been documented in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways Linking Fosamax to Osteonecrosis of the Jaw

The exact mechanism by which Fosamax leads to ONJ is not fully understood, but several pathways have been proposed. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw. They inhibit osteoclast activity, which can suppress normal bone remodeling and repair. This suppression may impair the ability of the jawbone to heal after minor trauma, such as tooth extraction. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone and contributing to necrosis. The multiscale characterization of jawbone in animal studies has provided comprehensive information that can help better understand jawbone-specific responses to bisphosphonate therapy (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Risk Factors and Adequacy of Warnings

Known risk factors for ONJ in patients taking Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings regarding Fosamax and ONJ has been a subject of legal scrutiny. The prescribing information for Fosamax includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, some patients and legal claims have argued that the warnings were insufficient to alert patients and healthcare providers to the risk, particularly in the context of routine dental procedures.

Settlement-Related Considerations for Affected Patients

Settlement criteria for Fosamax ONJ claims typically require evidence that the patient used Fosamax, developed ONJ, and that the ONJ was caused by the medication. The timeline between exposure and documented harm is a key factor. The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients must also demonstrate that they experienced harm, such as pain, infection, or the need for surgical intervention. Legal settlements may consider the severity of the ONJ, the duration of treatment, and the presence of other risk factors. Patients should consult with a legal professional to understand the specific criteria for their case.

Timeline Between Exposure and Documented Harm

The timeline between starting Fosamax and developing ONJ is variable. Symptoms can appear as early as one day after initiation or may take several months to develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In many cases, ONJ is triggered by a dental procedure, such as a tooth extraction, which can occur months or years after starting the medication. The risk of ONJ may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients considering legal action, documenting the date of first Fosamax use, the date of any dental procedures, and the date of ONJ diagnosis is essential.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it related to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis. A known adverse effect is osteonecrosis of the jaw (ONJ), a condition where exposed bone in the jaw fails to heal within eight weeks. The risk is associated with long-term use and dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the settlement criteria for Fosamax ONJ claims?

Settlement criteria typically require evidence of Fosamax use, a confirmed ONJ diagnosis, and a causal link. Key factors include the timeline between exposure and harm, severity of ONJ, duration of treatment, and presence of other risk factors. Patients should consult a legal professional (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.